Mao, Y. et al. The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating. Cancer Immunol. Immunother. 72, 2483–2498 (2023).
Google ScholarÂ
Ochoa de Olza, M., Navarro Rodrigo, B., Zimmermann, S. & Coukos, G. Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. Lancet Oncol. 21, e419–e430 (2020).
Google ScholarÂ
Wu, B., Zhang, B., Li, B., Wu, H. & Jiang, M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct. Target. Ther. 9, 274 (2024).
Google ScholarÂ
Galluzzi, L., Smith, K. N., Liston, A. & Garg, A. D. The diversity of CD8+ T cell dysfunction in cancer and viral infection. Nat. Rev. Immunol. 25, 662–679 (2025).
Google ScholarÂ
Hanahan, D., Michielin, O. & Pittet, M. J. Convergent inducers and effectors of T cell paralysis in the tumour microenvironment. Nat. Rev. Cancer 25, 41–58 (2025).
Google ScholarÂ
Zhou, Y., Shen, G., Zhou, X. & Li, J. Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity. Signal Transduct. Target. Ther. 10, 178 (2025).
Google ScholarÂ
Kwak, J. W. & Houghton, A. M. Targeting neutrophils for cancer therapy. Nat. Rev. Drug Discov. 24, 666–684 (2025).
Google ScholarÂ
Ng, M. S. F. et al. Deterministic reprogramming of neutrophils within tumors. Science 383, eadf6493 (2024).
Google ScholarÂ
Veglia, F. et al. Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. J. Exp. Med. 218, e20201803 (2021).
Google ScholarÂ
Wang, P. F. et al. Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: a meta-analysis of 40 studies. Oncoimmunology 7, e1494113 (2018).
Google ScholarÂ
Li, T. et al. Targeting MDSC for immune-checkpoint blockade in cancer immunotherapy: current progress and new prospects. Clin. Med. Insights Oncol. 15, 11795549211035540 (2021).
Google ScholarÂ
Nagaraj, S., Schrum, A. G., Cho, H. I., Celis, E. & Gabrilovich, D. I. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J. Immunol. 184, 3106–3116 (2010).
Google ScholarÂ
Comas-Casellas, E. et al. Cloning and characterization of CD300d, a novel member of the human CD300 family of immune receptors. J. Biol. Chem. 287, 9682–9693 (2012).
Google ScholarÂ
Wang, C. et al. CD300ld on neutrophils is required for tumour-driven immune suppression. Nature 621, 830–839 (2023).
Google ScholarÂ
Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493–500 (2024).
Google ScholarÂ
Vitalle, J., Terren, I., Orrantia, A., Zenarruzabeitia, O. & Borrego, F. CD300 receptor family in viral infections. Eur. J. Immunol. 49, 364–374 (2019).
Google ScholarÂ
Borrego, F. The CD300 molecules: an emerging family of regulators of the immune system. Blood 121, 1951–1960 (2013).
Google ScholarÂ
Leventis, P. A. & Grinstein, S. The distribution and function of phosphatidylserine in cellular membranes. Annu. Rev. Biophys. 39, 407–427 (2010).
Google ScholarÂ
Fischer, K. et al. Antigen recognition induces phosphatidylserine exposure on the cell surface of human CD8+ T cells. Blood 108, 4094–4101 (2006).
Google ScholarÂ
Elliott, J. I. et al. Membrane phosphatidylserine distribution as a non-apoptotic signalling mechanism in lymphocytes. Nat. Cell Biol. 7, 808–816 (2005).
Google ScholarÂ
Murakami, Y. et al. CD300b regulates the phagocytosis of apoptotic cells via phosphatidylserine recognition. Cell Death Differ. 21, 1746–1757 (2014).
Google ScholarÂ
Choi, S. C. et al. Cutting edge: mouse CD300f (CMRF-35-like molecule-1) recognizes outer membrane-exposed phosphatidylserine and can promote phagocytosis. J. Immunol. 187, 3483–3487 (2011).
Google ScholarÂ
Simhadri, V. R. et al. Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells. Blood 119, 2799–2809 (2012).
Google ScholarÂ
Naeini, M. B., Bianconi, V., Pirro, M. & Sahebkar, A. The role of phosphatidylserine recognition receptors in multiple biological functions. Cell. Mol. Biol. Lett. 25, 23 (2020).
Google ScholarÂ
Yin, Y., Huang, X., Lynn, K. D. & Thorpe, P. E. Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation. Cancer Immunol. Res. 1, 256–268 (2013).
Google ScholarÂ
Ly, K. I. et al. Bavituximab decreases immunosuppressive myeloid-derived suppressor cells in newly diagnosed glioblastoma patients. Clin. Cancer Res. 29, 3017–3025 (2023).
Google ScholarÂ
Hsiehchen, D. et al. The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial. Nat. Commun. 15, 2178 (2024).
Google ScholarÂ
Nagata, S. Apoptosis and clearance of apoptotic cells. Annu. Rev. Immunol. 36, 489–517 (2018).
Google ScholarÂ
Wang, W. et al. Mobilizing phospholipids on tumor plasma membrane implicates phosphatidylserine externalization blockade for cancer immunotherapy. Cell Rep. 41, 111582 (2022).
Google ScholarÂ
Chow, A. et al. Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity. Cancer Cell 39, 973–988 (2021).
Google ScholarÂ
MacDonald, A. et al. Delivery of IL-2 to the T cell surface through phosphatidylserine permits robust expansion of CD8 T cells. Front. Immunol. 12, 755995 (2021).
Google ScholarÂ
Pagliano, O. et al. Tim-3 mediates T cell trogocytosis to limit antitumor immunity. J. Clin. Invest. 132, e152864 (2022).
Google ScholarÂ
Wu, N., Song, H. & Veillette, A. Plasma membrane lipid scrambling causing phosphatidylserine exposure negatively regulates NK cell activation. Cell. Mol. Immunol. 18, 686–697 (2021).
Google ScholarÂ
Pasqual, G. et al. Monitoring T cell-dendritic cell interactions in vivo by intercellular enzymatic labelling. Nature 553, 496–500 (2018).
Google ScholarÂ
Nakandakari-Higa, S. et al. Universal recording of immune cell interactions in vivo. Nature 627, 399–406 (2024).
Google ScholarÂ
Nikghalb, K. D. et al. Expanding the scope of sortase-mediated ligations by using sortase homologues. ChemBioChem 19, 185–195 (2018).
Google ScholarÂ
Du, Y. et al. Membrane-anchored DNA nanojunctions enable closer antigen-presenting cell-T-cell contact in elevated T-cell receptor triggering. Nat. Nanotechnol. 18, 818–827 (2023).
Google ScholarÂ
Schraivogel, D. et al. High-speed fluorescence image-enabled cell sorting. Science 375, 315–320 (2022).
Google ScholarÂ
Barras, D. et al. Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T–myeloid cell networks in melanoma. Sci. Immunol. 9, eadg7995 (2024).
Google ScholarÂ
Cohen, M. et al. The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response. Nat. Cancer 3, 303–317 (2022).
Google ScholarÂ
Otsuji, M., Kimura, Y., Aoe, T., Okamoto, Y. & Saito, T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 ζ chain of T-cell receptor complex and antigen-specific T-cell responses. Proc. Natl Acad. Sci. USA 93, 13119–13124 (1996).
Google ScholarÂ
Nagaraj, S. et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13, 828–835 (2007).
Google ScholarÂ
Kumar, V., Patel, S., Tcyganov, E. & Gabrilovich, D. I. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37, 208–220 (2016).
Google ScholarÂ
Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268 (2012).
Google ScholarÂ
Zimmermann, I. et al. Synthetic single domain antibodies for the conformational trapping of membrane proteins. eLife 7, e34317 (2018).
Google ScholarÂ
Zhu, J. et al. Tumour immune rejection triggered by activation of α2-adrenergic receptors. Nature 618, 607–615 (2023).
Google ScholarÂ
Benguigui, M. et al. Interferon-stimulated neutrophils as a predictor of immunotherapy response. Cancer Cell 42, 253–265 (2024).
Google ScholarÂ
Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).
Google ScholarÂ
Gide, T. N. et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy. Cancer Cell 35, 238–255 (2019).
Google ScholarÂ
Prat, A. et al. Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Cancer Res. 77, 3540–3550 (2017).
Google ScholarÂ
Bagchi, S., Yuan, R. & Engleman, E. G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16, 223–249 (2021).
Google ScholarÂ
Schoenfeld, A. J. & Hellmann, M. D. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37, 443–455 (2020).
Google ScholarÂ
Eruslanov, E., Nefedova, Y. & Gabrilovich, D. I. The heterogeneity of neutrophils in cancer and its implication for therapeutic targeting. Nat. Immunol. 26, 17–28 (2025).
Google ScholarÂ
Kusmartsev, S., Nefedova, Y., Yoder, D. & Gabrilovich, D. I. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172, 989–999 (2004).
Google ScholarÂ
Si, Y. et al. Multidimensional imaging provides evidence for down-regulation of T cell effector function by MDSC in human cancer tissue. Sci. Immunol. 4, eaaw9159 (2019).
Google ScholarÂ
Elliott, J. I. et al. Phosphatidylserine exposure in B lymphocytes: a role for lipid packing. Blood 108, 1611–1617 (2006).
Google ScholarÂ
Rudd-Schmidt, J. A. et al. Lipid order and charge protect killer T cells from accidental death. Nat. Commun. 10, 5396 (2019).
Google ScholarÂ
Yan, Z., Wang, C., Wu, J., Wang, J. & Ma, T. TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives. Mol. Biomed. 6, 27 (2025).
Google ScholarÂ
McNutt, A. T. et al. GNINA 1.0: molecular docking with deep learning. J. Cheminformatics 13, 43 (2021).
Google ScholarÂ
Susila, H. et al. In vitro assays to evaluate specificity and affinity in protein–phospholipid interactions. Bio Protoc. 12, e4421 (2022).
Google ScholarÂ
Maier, J. A. et al. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J. Chem. Theory Comput. 11, 3696–3713 (2015).
Google ScholarÂ
Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A. & Case, D. A. Development and testing of a general amber force field. J. Comput. Chem. 25, 1157–1174 (2004).
Google ScholarÂ
Zhou, J. et al. Structural insights into the mechanism of GTP initiation of microtubule assembly. Nat. Commun. 14, 5980 (2023).
Google ScholarÂ
Roe, D. R. & Cheatham, T. E. III. Parallelization of CPPTRAJ enables large scale analysis of molecular dynamics trajectory data. J. Comput. Chem. 39, 2110–2117 (2018).
Google ScholarÂ
Miller, B. R. III et al. MMPBSA.py: an efficient program for end-state free energy calculations. J. Chem. Theory Comput. 8, 3314–3321 (2012).
Google ScholarÂ
Zimmermann, I. et al. Generation of synthetic nanobodies against delicate proteins. Nat. Protoc. 15, 1707–1741 (2020).
Google ScholarÂ
Andreatta, M. et al. Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nat. Commun. 12, 2965 (2021).
Google ScholarÂ
Zheng, L. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 374, abe6474 (2021).
Google ScholarÂ
Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773–782 (2019).
Google ScholarÂ
